GHRS (GH Research PLC) Short-Term Debt to Capital

Corporate company logo of GH Research PLC (GHRS)

The market trend for GH Research PLC (GHRS) shares reflects the dynamics of a company developing inhalation antidepressants protected by global patents, where the indicator stands at 0.00. The development of innovative psychedelics is currently in the testing phase, carving a high-risk path toward market entry. Business success depends on the results of medical trials, remaining virtually independent of market cycles and macroeconomics.

Ratio of Short-Term Indebtedness to Capital: GH Research Corp (GHRS) for 07/04/2022 - 10/31/2026

Analytical breakdowns for GH Research PLC

- stock quotes and analyst forecast:
Stock Price GH Research Corp|GHRS - Fair Value Consensus
- business market valuation indicators:
Market Capitalization GH Research plc|GHRS - Enterprise Value
- book capitalization information:
Net Assets per Single Share GH Research|GHRS - Accounting Value of Company|Market Value to Book Value Ratio ghres.com|GHRS - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital GH Research PLC|GHRS - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio GH Research|GHRS - Aggregate Debt Obligations|Debt to Book Capitalization Ratio GH Research plc|GHRS - Long-Term Liabilities|Company Short-Term Debt GH Research|Quick Liquidity Indicator ghres.com
- company profitability and valuation multiples indicators:
GHRS - Company Net Income
Fundamental valuation:GHRS GH Research Corp
Brand item of GH Research plc

This indicator measures the proportion of short-term borrowings within the equity structure, determining the company's reliance on the operational refinancing of liabilities. For GH Research PLC (GHRS), which invests in energy-efficient laboratories and ESG standards, this balance is critical for sustaining bioethical research without liquidity risk, a fact clearly reflected in the changing ratio of current liabilities to equity.

Competitor analysis for GH Research PLC

Short-Term Debt to Capital ALKS|AVDL (Avadel Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ATAI (Atai Life Sciences N.V.)|Short-Term Debt to Capital mindmed.co MNMD|CMPS - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital LBRX (LB Pharmaceuticals, Inc.)|Bright Minds Biosciences Inc (DRUG) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Vanda|CYBN (Cybin Inc) - Short-Term Debt to Capital|Short-Term Debt to Capital altoneuroscience.com|Short-Term Debt to Equity Ratio NRXP (NRx Pharmaceuticals, Inc.)|CING (cingulate.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Silo Pharma SILO|CPHI (China Pharma Holdings Inc.) - Current Liabilities to Equity|CMND - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient pacificbayminerals.com PBM|SPRC (SciSparc) - Short-Term Debt to Equity Ratio|Current Liabilities to Capital Seelos Therapeutics Inc. (SEEL)|VRPX (Virpax Pharmaceuticals Inc.) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Karuna Pharma (KRTX)